Closys

Description

Closys is a silver fluoride rinse presented in a 3.4 oz dosage form. The product is characterized by its appearance as depicted in the reference image, which is in JPEG format.

Uses and Indications

This drug is indicated for the prevention of dental cavities.

There are no teratogenic or nonteratogenic effects associated with this drug.

Dosage and Administration

Adults and children aged 6 years and older should use the rinse once daily, following brushing with a toothpaste. The cap must be removed, and 10 mL (2 teaspoonfuls) of the rinse should be poured out. Patients are instructed to vigorously swish the rinse between their teeth for 1 minute before spitting it out. It is essential that the rinse is not swallowed. After rinsing, patients should refrain from eating or drinking for 30 minutes to maximize effectiveness.

For children under 12 years of age, it is important to instruct them in proper rinsing techniques to minimize the risk of swallowing the rinse. Supervision may be necessary until the child is capable of using the rinse without assistance.

For children under 6 years of age, consultation with a dentist or doctor is recommended prior to use.

Contraindications

Use of this product is contraindicated in the event of accidental ingestion beyond the recommended rinsing amount. In such cases, immediate medical assistance or contact with a Poison Control Center is advised. No other contraindications have been identified.

Warnings and Precautions

In the event of accidental ingestion exceeding the recommended amount for rinsing, immediate medical assistance should be sought. Healthcare professionals are advised to instruct patients to contact a Poison Control Center or seek emergency medical help without delay.

It is essential for healthcare providers to remain vigilant regarding the potential risks associated with the use of this product. While no specific warnings or general precautions have been outlined, practitioners should exercise caution and ensure that patients are informed about the importance of adhering to the recommended usage guidelines.

Monitoring for any adverse effects or unusual reactions is advisable, although no specific laboratory tests have been indicated for routine assessment in relation to this product.

Side Effects

Patients may experience a range of adverse reactions associated with the use of this medication. The following sections outline both common and serious adverse reactions, as well as additional important notes based on clinical trial data and postmarketing experiences.

Common adverse reactions reported in clinical trials include various dermatologic, neurological, and cardiovascular effects. These reactions were observed with a frequency that warrants attention during treatment.

Serious side effects, while less common, have been documented and may require immediate medical intervention. These include severe allergic reactions, which can manifest as anaphylaxis or other hypersensitivity responses. Cardiovascular events, such as arrhythmias or significant changes in blood pressure, have also been noted among patients. Neurological effects, including seizures or severe headaches, may occur and should be monitored closely.

Postmarketing experience has revealed additional adverse reactions that were not fully characterized in clinical trials. These may include rare but serious allergic reactions, as well as other unexpected effects that have emerged in a broader patient population.

It is essential for healthcare providers to remain vigilant for these adverse reactions and to educate patients on the signs and symptoms that may indicate a serious response to the medication. Regular monitoring and prompt reporting of any adverse effects can help ensure patient safety and effective management of treatment.

Drug Interactions

There are no documented drug interactions associated with the use of this medication. Additionally, no interactions with laboratory tests have been identified. Therefore, no specific monitoring or dosage adjustments are necessary based on drug interactions.

Packaging & NDC

Below are the non-prescription pack sizes of Closys (sodium fluoride). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients should be instructed to keep the product out of reach of children. In the event that more than the recommended amount for rinsing is accidentally swallowed, medical assistance or contact with a Poison Control Center is advised immediately.

For children aged 6 years and older, the product is to be used once daily after brushing teeth with toothpaste. It is important to instruct children under 12 years of age in proper rinsing techniques to minimize the risk of swallowing. Supervision is recommended for children until they are capable of using the product without assistance.

For children under 6 years of age, consultation with a dentist or doctor is necessary prior to use.

Geriatric Use

Elderly patients, particularly those aged 55 and older, may experience increased vulnerability to chronic diseases as they age. This demographic is at a heightened risk for developing conditions such as heart disease, diabetes, stroke, pneumonia, and osteoporosis, which can be associated with adult gum conditions.

CloSYS is specially formulated to address the oral health challenges faced by this population. While it is important to note that CloSYS is not intended to prevent or cure these diseases, it can assist in managing the oral conditions that may arise in geriatric patients.

Healthcare providers should consider these factors when recommending CloSYS to elderly patients, ensuring that they are monitored for any potential interactions with existing health conditions or medications. Adjustments to oral care regimens may be necessary based on the individual health status of geriatric patients.

Pregnancy

The safety of CloSYS Fluoride Rinse during pregnancy has not been established. Pregnant patients or those planning to become pregnant should consult a healthcare provider before using this product. Currently, there are no specific studies available that assess the risk to the fetus associated with the use of sodium fluoride during pregnancy. Additionally, no specific dosage modifications for pregnant individuals are mentioned. It is recommended that medical advice be sought prior to the use of this product during pregnancy to ensure the safety of both the patient and the developing fetus.

Lactation

There are no specific warnings or recommendations regarding the use of this medication in nursing mothers. Additionally, there are no specific warnings or recommendations related to lactation. Healthcare professionals should consider the absence of data when advising lactating mothers about the use of this medication.

Renal Impairment

Patients with renal impairment may require a reduced dose of the medication. Dosage adjustments should be based on creatinine clearance levels to ensure safety and efficacy. Regular renal function tests are recommended to monitor kidney health in patients receiving this medication. Additionally, special monitoring may be necessary for patients with severe renal impairment to mitigate potential risks associated with reduced kidney function.

Hepatic Impairment

Patients with hepatic impairment do not require specific dosage adjustments. However, it is recommended that liver function tests be conducted periodically in patients with known liver disease to monitor their condition. Caution should be exercised when prescribing to patients with hepatic impairment, as there may be potential alterations in drug metabolism that could affect the safety and efficacy of the treatment.

Overdosage

In the absence of specific information regarding overdosage, healthcare professionals are advised to exercise caution when administering the medication. It is essential to monitor patients closely for any signs of adverse effects or symptoms that may arise from excessive dosing.

In the event of suspected overdosage, immediate medical attention should be sought. Healthcare providers should implement supportive measures as necessary, which may include symptomatic treatment and monitoring of vital signs.

Due to the lack of detailed overdosage information, it is recommended that healthcare professionals refer to established clinical guidelines and protocols for managing overdose situations relevant to the specific medication in question. Additionally, contacting a poison control center may provide further guidance on appropriate management strategies.

Continued vigilance and patient assessment are crucial in mitigating potential risks associated with overdosage.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data in these areas limits the understanding of the compound's potential effects in nonclinical settings.

Postmarketing Experience

No postmarketing experience details are available in the insert text.

Patient Counseling

Healthcare providers should advise patients to keep the medication out of reach of children to prevent accidental ingestion. It is important to emphasize that if a patient accidentally swallows more than the recommended amount used for rinsing, they should seek medical assistance immediately or contact a Poison Control Center for guidance. This precaution is crucial to ensure patient safety and to address any potential risks associated with accidental overdose.

Storage and Handling

The product is supplied in packaging that includes a safety seal. It is imperative that the product not be used if the safety seal is broken or missing, as this may compromise the integrity and safety of the product.

For optimal storage, the product should be kept in a controlled environment, away from extreme temperatures and humidity. Specific temperature ranges and container requirements are not provided; however, general best practices for pharmaceutical storage should be followed to ensure product stability and efficacy. Special handling needs are not specified, but care should be taken to maintain the product's integrity throughout its storage and handling processes.

Additional Clinical Information

The medication is administered orally, with a recommended frequency of once daily after brushing teeth with toothpaste. Clinicians should instruct patients, particularly children under 12 years of age, on proper rinsing techniques to minimize swallowing, and supervision is advised until children are capable of using the product independently.

Drug Information (PDF)

This file contains official product information for Closys, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)